The identification of clinically-relevant early diagnostic and prognostic protein biomarkers is essential to maximize therapeutic efficacy and prevent cancer progression. The aim of the current study is to determine whether aberrant plasma protein profile can be applied as a surrogate tool for early diagnosis of bladder carcinoma.
Ashish Kamat: Welcome to UroToday’s Bladder Cancer Center of Excellence. I’m Ashish Kamat, I’m a professor of urologic oncology at MD Anderson Cancer Center in Houston, Texas. And it gives me great pleasure to welcome today, Dr. Makarand Khochikar, who is Chief Urologic Oncologist at the Siddhi Vinayak Ganapati Cancer Hospital in Miraj. He’s also […]
San Francisco, CA (UroToday.com) – The Answer Cancer Foundation (AnCan) and Us Too International, which sponsor support groups for men with prostate cancer, announced a series of four webinars, Active Surveillance and Beyond, aimed at men on or considering active surveillance (AS) for low- and intermediate-risk prostate cancer in place of aggressive therapy.
Evidence on the incidence, prevalence, and outcomes of bone metastases among patients with systemic malignancy is limited. This study aimed to evaluate it using the Surveillance, Epidemiology, and End Results (SEER) database.
The purpose was to evaluate the dosimetric effects in prostate cancer treatment caused by anatomical changes occurring during the time frame of adaptive replanning in a magnetic resonance linear accelerator (MR-linac) workflow.
In this study, we aimed to determine the prevalence of lower urinary tract symptoms (LUTS) in patients with Behçet disease (BD) and to investigate the relationship between the severity of BD and LUTS.
The aim of this study was to study the clinical effectiveness of a structured home modeling (HM) protocol in Peyronie’s disease (PD) patients who have residual curvature up to 45° after inflatable penile prosthesis (PP) placement.
To describe the clinical characteristics of renal cell carcinoma (RCC) with venous tumor thrombus (VTT) and bland thrombus (BT), and to evaluate the influence of BT on surgical treatment and cancer-specific survival (CSS) of RCC with VTT.
To identify clear cell renal cell carcinoma-related gene mutations potentially associated with aggressive disease, sarcomatoid differentiation or poor prognosis. We carried out genomic analysis of 217 tumor foci from 25 patients with conventional clear cell renal cell carcinoma (14 patients), clear cell renal cell carcinoma with sarcomatoid differentiation (six patients) and non-clear cell renal cell […]
Intravesical bacillus Calmette-Guerin (BCG) therapy is the treatment of choice for patients with T1 or high-grade superficial bladder cancer or those with carcinoma in situ after transurethral resection.
